Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome

Blood Transfus. 2010 Jul;8(3):203-10. doi: 10.2450/2009.0101-09.

Authors

Domenica Caramazza¹, Gerlando Quintini, Ignazio Abbene, Lucio Lo Coco, Alessandra Malato, Rosa Di Trapani, Giorgia Saccullo, Giuseppina Pizzo, Roberto Palazzolo, Rita Barone, Giuseppina Mazzola, Sergio Rizzo, Paolo Ragonese, Paolo Aridon, Vincenzo Abbadessa, Sergio Siragusa

Affiliation

¹ Cattedra ed U.O. di Ematologia con trapianto, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone di Palermo Via del Vespro 127, I-90127 Palermo, Italy.

No abstract available

Publication types

Case Reports

MeSH terms

ADAM Proteins / blood
ADAMTS13 Protein
Adolescent
Adult
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Female
Humans
Immunologic Factors / therapeutic use
Male
Middle Aged
Purpura, Thrombotic Thrombocytopenic / drug therapy
Rituximab
Salvage Therapy / methods
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab
ADAM Proteins
ADAMTS13 Protein
ADAMTS13 protein, human

Supplementary concepts

Thrombotic thrombocytopenic purpura, acquired